RTP Mobile Logo
Submitted by web@researchtop... on Fri, 08/10/2012 - 10:30

These audio proceedings from an Independent Satellite Symposium held at the 2012 ASCO Annual meeting offer the perspectives of 5 renowned international clinical investigators on a number of controversial management and research issues.

This content is available in a number of formats for listening on the go with a mobile device or at home on a computer.

Listen to audio excerpts

Track 1: Introduction: Dr Love
Track 2: Review of audience polling results — ROS1 tumor translocation and responsiveness to crizotinib
Track 3: Forecast on the expanding roles of driver mutations and immune modulators in treatment selection for patients with non-small cell lung cancer (NSCLC)
Track 4: Faculty and audience poll: In which patients with metastatic NSCLC with tissue already accessed would you order EGFR or ALK testing?
Track 5: Faculty and audience poll: Outside of a clinical trial setting, do you believe there is a role for K-ras testing?
Track 6: Module 1, Dr Langer: Emerging implications of histology and molecular diagnostics in advanced NSCLC
Track 7: Current clinical implications of histopathologic diagnosis for systemic treatment decision-making — Squamous versus nonsquamous versus mixed adenosquamous
Track 8: K-ras: Investigational agents and perspective on current treatment approach
Track 9: Audience-generated question: Is blood-streaked sputum an absolute contraindication for administering bevacizumab?
Track 10: Faculty and audience poll: What would be your initial treatment for a 60-year-old minimally symptomatic patient with EGFR and ALK wild-type metastatic adenocarcinoma without bevacizumab contraindications?
Track 11: Faculty and audience poll: What maintenance treatment, if any, would you choose if the patient experienced a partial response (PR) to initial therapy?
Track 12: Faculty and audience poll: What is your immediate next treatment approach for a 60-year-old patient with metastatic adenocarcinoma who has received 2 cycles of carboplatin/paclitaxel/bevacizumab and whose EGFR test then returns positive for an exon 21 mutation?
Track 13: Module 2, Dr Socinski: Treatment for patients with EGFR wild-type nonsquamous NSCLC
Track 14: Faculty and audience poll: What are some later-line treatment options for a 60-year-old with progressive disease?
Track 15: Audience-generated question: Which chemotherapy is best for patients with K-ras mutation-positive NSCLC?
Track 16: Perspectives on efficacy and side effects of maintenance therapy in NSCLC
Track 17: Faculty and audience poll: What is the optimal treatment for a 60-year-old with slow but definite tumor progression on erlotinib?
Track 18: Faculty and audience poll: What initial therapy would you recommend for a 60-year-old patient with symptomatic EGFR mutation-positive disease but no bevacizumab contraindications?
Track 19: Faculty and audience poll: Should you do a lung biopsy for mutational analysis on an 88-year-old nonsmoker with bone pain and lung and bone metastases?
Track 20: Module 3, Dr Lynch: Treatment decision-making for patients with EGFR mutations, EML4-ALK translocations or ROS rearrangement
Track 21: Faculty and audience poll: What initial treatment strategy would you recommend for a 60-year-old patient with symptomatic EML4-ALK-positive disease and no bevacizumab contraindications?
Track 22: Audience-generated question: What are your thoughts on the spectrum of EGFR mutations, treatment for brain metastases and adjuvant erlotinib?
Track 23: Faculty and audience poll: What first-line chemotherapy regimen do you generally recommend for patients with metastatic squamous cell NSCLC?
Track 24: Module 4, Dr Sequist: Current and future management of advanced squamous cell NSCLC
Track 25: Audience-generated question: What are your thoughts on the risks of core biopsy, circulating tumor cells and driver mutations in small cell lung cancer?
Track 26: Audience-generated question: Where are we with the use of nab paclitaxel in squamous cell NSCLC?
Track 27: Audience-generated question: What are the data to support the use of erlotinib beyond progression?
Track 28: Faculty and audience poll: What is your preferred adjuvant treatment regimen for a 60- or 75-year-old with EGFR wild-type adenocarcinoma and 3 positive hilar nodes?
Track 29: Module 5, Dr Soria: Adjuvant treatment for NSCLC
Track 30: Audience-generated question: Should you rebiopsy after progression on erlotinib in a patient with EGFR mutation-positive adenocarcinoma and bone metastases?
Track 31: Audience-generated question: What treatment approach would the faculty recommend for a patient with ALK mutation-positive disease experiencing progression on crizotinib?
Track 32: Audience-generated question: What are your perspectives on VeriStrat®?
Track 33: Audience-generated question: What other important data sets will be presented at ASCO 2012 specific to NSCLC?

 
FACULTY:
 
Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
University of Pennsylvania
Vice Chair
Radiation Therapy Oncology Group
Philadelphia, Pennsylvania
 
Thomas J Lynch Jr, MD
Jonathan and Richard Sackler
Professor of Internal Medicine
Director, Yale Cancer Center
Physician-in-Chief
Smilow Cancer Hospital at
Yale New Haven
New Haven, Connecticut
 
Lecia V Sequist, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General
Hospital Cancer Center
Boston, Massachusetts
 
Mark A Socinski, MD
Professor of Medicine
and Thoracic Surgery
Director, Lung Cancer Section
Division of Hematology/Oncology
Co-Director
UPMC Lung Cancer Center of Excellence
Co-Director, Lung and Thoracic
Malignancies Program
University of Pittsburgh
UPMC Cancer Pavilion
Pittsburgh, Pennsylvania
 
Jean-Charles Soria, MD, PhD
Full Professor, Paris University XI
Division of Cancer Medicine
Institut Gustave Roussy
Villejuif, France
 
MODERATOR:
 
Neil Love, MD
Research To Practice
Miami, Florida